Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fosgonimeton

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Athira Pharma Presents LIFT-AD Trial Results At CTAD 2024
    Athira Pharma Presents LIFT-AD Trial Results At CTAD 2024

    22 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/22/2966783/0/en/Athira-Pharma-to-Present-Results-from-Phase-2-3-LIFT-AD-Clinical-Trial-of-Fosgonimeton-at-the-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-2024-Meeting.html

    GLOBENEWSWIRE
    22 Oct 2024
    Share Share
    Athira Pharma Reports Q2 2024 Results And Pipeline Updates
    Athira Pharma Reports Q2 2024 Results And Pipeline Updates

    01 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/01/2923179/0/en/Athira-Pharma-Reports-Second-Quarter-2024-Financial-Results-and-Pipeline-and-Business-Updates.html

    GLOBENEWSWIRE
    01 Aug 2024
    Share Share
    Athira To Host Webinar On Fosgonimeton For Alzheimer's Disease
    Athira To Host Webinar On Fosgonimeton For Alzheimer's Disease

    12 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/12/2897428/0/en/Athira-to-Host-Webinar-Highlighting-Potential-for-Fosgonimeton-to-Protect-and-Preserve-Neuronal-Health-in-Mild-to-Moderate-Alzheimer-s-Disease-Patients.html

    GLOBENEWSWIRE
    12 Jun 2024
    Share Share
    Athira: Fosgonimeton Alzheimer's Preclinical Data Published
    Athira: Fosgonimeton Alzheimer's Preclinical Data Published

    11 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/11/2861365/0/en/Athira-Pharma-Announces-Publication-of-Preclinical-Data-Highlighting-Fosgonimeton-Treatment-in-Models-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    11 Apr 2024
    Share Share
    Athira Presents Data Supporting Therapeutic Potential of Fosgonimeton
    Athira Presents Data Supporting Therapeutic Potential of Fosgonimeton

    08 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/08/2843025/0/en/Athira-Pharma-Presents-Clinical-and-Preclinical-Data-Supporting-Therapeutic-Potential-of-Fosgonimeton-in-Alzheimer-s-and-Parkinson-s-Diseases-at-AD-PD-2024-International-Conference.html

    GLOBENEWSWIRE
    08 Mar 2024
    Share Share
    Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Trial of Fosgonimeton
    Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Trial of Fosgonimeton

    03 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/03/2803137/0/en/Athira-Pharma-Completes-Enrollment-of-Phase-2-3-LIFT-AD-Clinical-Trial-of-Fosgonimeton-in-Mild-to-Moderate-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    03 Jan 2024
    Share Share